Plant Name: Capsella bursa-pastoris
Taxonomic Information:
Plant ID: NPO26429
Plant Latin Name: Capsella bursa-pastoris
Taxonomy Genus: Capsella
Taxonomy Family: Brassicaceae
Plant External Links:
NCBI TaxonomyDB:
3719
Plant-of-the-World-Online:
30092589-2
Used in Medicines:
Country/Region:
India; RussiaTraditional Medicine System:
Indian Folk; HomeopathyMedicinal Functions:
Antiscorbutic; Astringent; Cancer; Diuretic; Emmenagogue; Haemostatic; Homeopathy; Hypotensive; Oxytoxic; Stimulant; Vasoconstrictor; Vasodilator; Vulnerary
Geographical Distribution:
Brazil; Turkey; Italy; Bangladesh; Kenya; Sudan; Nepal; France; Ethiopia; Rwanda; Ireland; Bolivia; Norway; Ecuador; Saudi Arabia; Belarus; Algeria; Cuba; Iceland; Austria; Russia; United States; Zimbabwe; Germany; Chile; Belgium; Dominican Republic; Tanzania; Spain; Ukraine; Eritrea; Netherlands; Uganda; Libya; Pakistan; Denmark; Poland; Finland; Mauritius; Morocco; Sweden; Namibia; Japan; Switzerland; Haiti; Bulgaria; Jamaica; Romania; Albania; Honduras; Portugal; Mexico; Egypt; South Africa; India; Peru; Lesotho; Djibouti; Tunisia; Colombia; Greece; Burundi; Hungary; Taiwan; Cyprus
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CHRM1; CHRM2; CHRM3; CHRM4; CHRM5; | |
| TSHR; | |
| TDP1; MIF; | |
| MAPK1; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | MIF | Macrophage migration inhibitory factor | P14174 | CHEMBL2085 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Small molecule receptor (family A GPCR) | CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 | CHEMBL216 |
| Small molecule receptor (family A GPCR) | CHRM2 | Muscarinic acetylcholine receptor M2 | P08172 | CHEMBL211 |
| Small molecule receptor (family A GPCR) | CHRM3 | Muscarinic acetylcholine receptor M3 | P20309 | CHEMBL245 |
| Small molecule receptor (family A GPCR) | CHRM4 | Muscarinic acetylcholine receptor M4 | P08173 | CHEMBL1821 |
| Small molecule receptor (family A GPCR) | CHRM5 | Muscarinic acetylcholine receptor M5 | P08912 | CHEMBL2035 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0023052; signaling | GO:0007271; synaptic transmission, cholinergic | 9.041E-13 | 2.461E-09 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| CC | GO:0044456; synapse part | GO:0045211; postsynaptic membrane | 3.576E-08 | 3.539E-05 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| BP | GO:0008283; cell proliferation | GO:0008283; cell proliferation | 2.778E-07 | 2.161E-04 | CHRM1, CHRM3, CHRM4, CHRM5, MAPK1, MIF |
| MF | GO:0003824; catalytic activity | GO:0004435; phosphatidylinositol phospholipase C activity | 2.904E-07 | 2.180E-04 | CHRM1, CHRM3, CHRM5 |
| BP | GO:0032501; multicellular organismal process | GO:0046541; saliva secretion | 2.410E-06 | 1.640E-03 | CHRM1, CHRM3 |
| CC | GO:0044456; synapse part | GO:0043679; axon terminus | 2.585E-06 | 1.705E-03 | CHRM1, CHRM2, CHRM3 |
| CC | GO:0045202; synapse | GO:0032279; asymmetric synapse | 6.743E-06 | 3.765E-03 | CHRM2, CHRM3 |
| BP | Unclassified; | GO:0003056; regulation of vascular smooth muscle contraction | 8.667E-06 | 4.718E-03 | CHRM1, CHRM3 |
| CC | GO:0030054; cell junction | GO:0030054; cell junction | 1.002E-05 | 5.324E-03 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, MAPK1 |
| BP | GO:0032501; multicellular organismal process | GO:0007399; nervous system development | 1.507E-05 | 6.981E-03 | CHRM1, CHRM2, CHRM3, TSHR |
| BP | GO:0050896; response to stimulus | GO:0007197; adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway | 1.125E-17 | 1.225E-13 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| MF | GO:0060089; molecular transducer activity | GO:0016907; G-protein coupled acetylcholine receptor activity | 1.125E-17 | 1.225E-13 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| BP | GO:0050896; response to stimulus | GO:0007207; phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway | 6.750E-17 | 4.899E-13 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 5.258E-12 | 5.310E-10 | CHRM2, CHRM3, CHRM1, CHRM4, CHRM5, MAPK1 |
| 09140 Cellular Processes | 09142 Cell motility | hsa04810 | Regulation of actin cytoskeleton | 2.835E-10 | 1.432E-08 | CHRM2, CHRM3, CHRM1, CHRM4, CHRM5, MAPK1 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.341E-09 | 4.513E-08 | CHRM2, CHRM3, CHRM1, CHRM4, CHRM5, TSHR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 1.277E-06 | 3.226E-05 | CHRM2, CHRM3, CHRM1, CHRM5 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.906E-06 | 3.850E-05 | CHRM2, CHRM1, MAPK1, TSHR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 5.394E-04 | 9.080E-03 | CHRM2, CHRM1, MAPK1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| L00-L99: Diseases of the skin and subcutaneous tissue | Seborrhea | L21 | CHRM3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CHRM1; CHRM5; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Postoperative nausea and vomiting | R11 | CHRM3; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | CHRM2; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Refractory autoimmune diseases | D84.9, M35.9 | MIF; |
| K00-K95: Diseases of the digestive system | Colitis | K50-K52 | CHRM5; |
| J00-J99: Diseases of the respiratory system | Bronchodilator | J45 | CHRM4; |
| C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | CHRM3; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | CHRM4; |
| G00-G99: Diseases of the nervous system G00-G99 | Brain diseases | G00-G99 | CHRM5; |
| H00-H59: Diseases of the eye and adnexa | Produce mydriasis and cycloplegia for diagnostic purposes | H57.04 | CHRM4; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnosing bronchial hyperreactivity | W88 | CHRM3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CHRM1; CHRM3; CHRM4; |
| NA: NA | Peptic ulcer disease | NA | CHRM4; |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | CHRM1; CHRM2; CHRM4; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | CHRM1; CHRM5; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | CHRM4; |
| NA: NA | Gastritis | NA | CHRM4; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | CHRM1; CHRM3; CHRM4; |
| N00-N99: Diseases of the genitourinary system | Overactive bladder | N32.81 | CHRM3; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | CHRM1; CHRM3; CHRM4; CHRM5; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | MIF; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | CHRM4; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Organophosphate poisoning | T60.0 | CHRM4; |
| H00-H59: Diseases of the eye and adnexa | Acquired nystagmus | H55 | CHRM4; |
| NA: NA | Abdominal stomach pain | NA | CHRM1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | CHRM4; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | CHRM1; CHRM2; CHRM4; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CHRM3; |
| J00-J99: Diseases of the respiratory system | Obstructive lung diseases | J40-J44, J47 | CHRM3; |
| G00-G99: Diseases of the nervous system G00-G99 | Central and peripheral nervous diseases | G96.9 | CHRM4; CHRM5; |
| NA: NA | Addiction | NA | CHRM2; |
| NA: NA | Extrapyramidal disorders secondary to neuroleptic drug therapy | NA | CHRM1; |
| NA: NA | Excessive sweating | NA | CHRM1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nocturia | R35 | CHRM4; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CHRM1; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | CHRM1; CHRM5; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | CHRM5; |
| NA: NA | Dystonia | NA | CHRM1; |
| NA: NA | Dysuria | NA | CHRM4; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | CHRM2; CHRM4; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | CHRM4; |
| H00-H59: Diseases of the eye and adnexa | Mydriasis diagnosis | H57.0 | CHRM4; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | CHRM5; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | CHRM1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Urinary retention | R33 | CHRM4; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | CHRM1; CHRM2; CHRM3; CHRM5; |
| NA: NA | Urgency | NA | CHRM4; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MIF; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | CHRM1; |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | CHRM4; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | CHRM1; CHRM4; CHRM5; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Visceral spasms | R25.2 | CHRM1; |
| NA: NA | Vomiting | NA | CHRM4; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Amnesia | F04 | CHRM5; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | CHRM5; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | CHRM1; CHRM2; CHRM3; CHRM4; |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | CHRM4; |
| NA: NA | Functional bowel syndrome | NA | CHRM1; |
| NA: NA | Uveitis | NA | CHRM4; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Stabilize muscle contractions | M00-M99 | CHRM2; |
| K00-K95: Diseases of the digestive system | Stomach ulcer | K25-K27 | CHRM1; CHRM5; |
| NA: NA | Suprapubic pain | NA | CHRM4; |
| NA: NA | Spasms | NA | CHRM3; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | CHRM2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Sjogren's syndrome | M35.0 | CHRM3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | CHRM4; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CHRM4; MAPK1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | CHRM4; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | CHRM2; |
| NA: NA | Moderate and severe psychomotor agitation | NA | CHRM4; |
| NA: NA | Schizoaffective disorders | NA | CHRM1; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
